Stockreport

Dermira Presents New Scientific Research Findings from the Lebrikizumab Program at Leading International Itch Conference

Journey Medical Corporation  (DERM) 
Last journey medical corporation earnings: 11/5 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: investor.dermira.com
PDF - New findings in human sensory neurons highlight role of IL-13 in amplifying itch and lebrikizumab’s role in inhibiting itch signals in atopic dermatitis- Lebrikizumab [Read more]